公开(公告)号：EP1915367A1

公开(公告)日：2008-04-30

申请号：EP06765225.5

申请日：2006-08-07

申请人： AstraZeneca AB

发明人： MCKERRECHER, Darren ,  PIKE, Kurt, Gordon ,  WARING, Michael, James

IPC分类号： C07D403/12 ,  C07D405/14 ,  A61K31/41 ,  A61P3/00

CPC分类号： C07D403/12 ,  C07D405/14

摘要： Compounds of formula (I) wherein R1, R2, R3 and HET-1 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

摘要翻译： 其中R 1，R 2，R 3和HET-1如说明书中所述的式（I）化合物及其盐是葡萄糖激酶（GLK）的活化剂并因此可用于治疗例如2型糖尿病。 还描述了制备式（I）化合物的方法。

公开(公告)号：EP1891069A1

公开(公告)日：2008-02-27

申请号：EP06727138.7

申请日：2006-05-19

申请人： AstraZeneca AB

发明人： CAULKETT, Peter, William, Rodney ,  MCKERRECHER, Darren ,  NEWCOMBE, Nicholas, John ,  PIKE, Kurt, Gordon ,  WARING, Michael, James

IPC分类号： C07D473/00 ,  C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61P3/08

CPC分类号： C07D471/04 ,  C07D473/00 ,  C07D487/04

摘要： Compounds of Formula (I), wherein R1- R10, A and X1 to X3 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

公开(公告)号：EP1928874A1

公开(公告)日：2008-06-11

申请号：EP06779396.8

申请日：2006-09-12

申请人： AstraZeneca AB

发明人： CAULKETT, Peter, William, Rodney ,  MCKERRECHER, Darren ,  NEWCOMBE, Nicholas, John ,  PIKE, Kurt, Gordon ,  ROBB, Graeme, Richard ,  WARING, Michael, James

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/4985 ,  A61P3/10

CPC分类号： C07D471/04 ,  C07D487/04

摘要： Compounds of Formula (I) wherein R1 to R11, A and X1 to X3 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.

公开(公告)号：EP1954690B1

公开(公告)日：2013-05-15

申请号：EP06794783.8

申请日：2006-10-17

申请人： AstraZeneca AB

发明人： ANDREWS, David, Michael ,  STOKES, Elaine Sophie Elizabeth ,  TURNER, Andrew ,  WARING, Michael, James

IPC分类号： C07D401/06 ,  A61P35/00 ,  A61K31/454

CPC分类号： C07D401/06

公开(公告)号：EP2324028A2

公开(公告)日：2011-05-25

申请号：EP09785441.8

申请日：2009-08-03

申请人： AstraZeneca AB

发明人： BENNETT, Stuart, Norman, Lile ,  BONN, Peter, Gustaf ,  BRINK, Mikael, Dan ,  BUTLIN, Roger, John ,  CAMPBELL, Leonie ,  DAVIES, Robert, Darren, Morse ,  FÄGERHAG, Jonas, Rickard ,  JURVA, Ulrik ,  POINTON, Helen, Claire ,  ROBB, Graeme, Richard ,  SCHNECKE, Volker ,  SVENSSON HENRIKSSON, Anette Marie ,  WALKER, Rolf, Peter ,  WARING, Michael, James ,  WESTERLUND, Christer, Ralf

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P3/04 ,  A61P3/10

CPC分类号： C07D487/04

摘要： A compound of Formula (I) is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

公开(公告)号：EP2190840A2

公开(公告)日：2010-06-02

申请号：EP08788687.5

申请日：2008-08-15

申请人： AstraZeneca AB

发明人： BIRCH, Alan, Martin ,  BUTLIN, Roger, John ,  GILL, Adrian, Liam ,  GROOMBRIDGE, Samuel, David ,  PLOWRIGHT, Alleyn, Thomas ,  WARING, Michael, James

IPC分类号： C07D413/12 ,  A61K31/4245 ,  A61P3/00

CPC分类号： C07D413/12

摘要： Compounds of formula (I), or pharmaceutically-acceptable salts and/or pro-drugs thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein n is 0 to 3; p is 0 or 1; q is 0 to 2; R1and R2are, for example, independently fluoro, chloro, bromo, cyano or (1-4C)alkyl; X is -O-, -S- or -NRa- wherein Ra is hydrogen or (1-4C)alkyl; RA1 and RA2 are, for example, independently hydrogen or (1-4C)alkyl; Ring A is a di-linked ring or ring system chosen from (4-6C)cycloalkane, (7- 10C)bicycloalkane and (8-12C)tricycloalkane each optionally substituted, for example, by one substituent selected from (1-4C)alkyl, (1-4C)alkoxy and (1-4C)alkoxy(1-4C)alkyl; or Ring A is phenylene optionally substituted, for example, by up to four substituents selected from fluoro, chloro, bromo, cyano, (1-4C)alkyl, (1-4C)alkoxy and (1- 4C)alkoxy(1-4C)alkyl; togetherwith processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.